ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Background: In patients with COPD on ICS/LABA, GOLD recommends a step up to ICS/LAMA/LABA in those with exacerbations or a switch to LAMA/LABA in those with major symptoms. It is unclear if a switch to LAMA/LABA may confer greater exacerbation risk vs a step up to ICS/LAMA/LABA.

Aim: To evaluate stepping up to ICS/LAMA/LABA vs switching to LAMA/LABA or staying on ICS/LABA in KRONOS (in which 74% of patients had no recent exacerbations).

Methods: In KRONOS (NCT02497001), symptomatic patients with moderate-to-very severe COPD (exacerbations in the prior year not required) were randomized to budesonide/glycopyrronium/formoterol fumarate dihydrate 320/14.4/10 µg (BGF), glycopyrronium/formoterol fumarate dihydrate 14.4/10 µg (GFF) or budesonide/formoterol fumarate dihydrate 320/10 µg (BFF) via MDI, or budesonide/formoterol fumarate dihydrate 400/12 µg via DPI (BUD/FORM) for 24 weeks. Lung function and moderate/severe exacerbation rates were analyzed post hoc in patients on ICS/LABA in the 30 days before screening.

Results: On stepping up to BGF, while lung function was similar vs switching to GFF, exacerbation risk was substantially reduced; lung function benefits were greater and exacerbation risk was numerically reduced with BGF vs BFF or BUD/FORM (Table).

Conclusion: In this analysis, symptomatic patients on ICS/LABA had reduced exacerbation risk from a step up to ICS/LAMA/LABA vs a switch to LAMA/LABA.

Abstract

#{title}